Partnering opportunities
The Walter and Eliza Hall Institute (WEHI) has more than 300 projects in immunology, cancer and infectious disease feeding into its discovery and development pipelines. We are committed to translation of our discoveries into improvements in disease diagnosis, prevention and treatment and have a strong track record of successful development projects with both the private and public sectors.
We have a portfolio of projects potentially available for licensing or collaboration, that includes enabling technologies, drug targets, chemical and biological agents with proof of efficacy, through to projects in Phase II clinical development.
Available opportunities
- Cancer
- Infectious diseases
- Immunology/Autoimmunity
- Technology platforms
- Spin-out companies
Contact
For more information about these or other partnering opportunities contact:
Dr Julian Clark
Head, Business Development
Tel: +61 3 9345 2612
Dr Kurt Lackovic
Business Development Manager
Tel: +61 3 9345 2129
Cancer
A new means of jointly targeting IGF-1R and IR in cancer
- Exploits a common druggable site on the extracellular surface of the Type 1 insulin-like growth factor receptor and the insulin receptor (IGF-1R and IR)
- Suitable for targeting by small molecules
- Offers advantages over antibody- and tyrosine kinase inhibitor-based strategies
Updated: October 2012
For more information, download the printable flyer.
A novel class of JAK inhibitors
- Novel druggable site identified on JAK
- Potential to develop non-competitive small-molecule JAK inhibitors
- Offers advantages over current strategies
Updated: October 2012
For more information, download the printable flyer.
Back to top
Infectious diseases
Novel anti-HIV compounds – frameshift modulators
- Unique approach to target HIV – HIV gene translation
- Targeted mechanism is HIV frameshifting
- Compounds that modulate HIV frameshifting identified
Updated: October 2012
For more information, download the printable flyer.
Anti-fungal drug development – two novel strategies
- Opportunistic fungal infections on the rise
- Efflux pumps critical to emerging fungal drug resistance
- Pump inhibitors and new class of anti-fungal agents identified
Updated: October 2012
For more information, download the printable flyer.
Back to top
Technology platforms
Novel antibody generation platform
- In vivo generation of murine antibodies against difficult targets (e.g. self-antigens)
- Circumvents need to generate specific gene knockouts
Updated: October 2012
For more information, download the printable flyer.
Antibody Facility: Victorian Antibody Initiative
- Fast access to high quality novel antibodies has just become easier
- A joint initiative between the Walter and Eliza Hall Institute and Monash University now provides the biomedical research community with an antibody partner fully attuned to the demands of world-class science
Updated: December 2012
For more information, download the printable flyer.
High-Throughput Chemical Screening Facility
- The Walter and Eliza Hall Institute’s High-Throughput Chemical Screening Facility has everything in place to help you through the early stages of drug discovery and development
Updated: October 2012
For more information, download the printable flyer.
Back to top
Spin-out companies
BACE Therapeutics: β-secretase (BACE1) inhibitors for treatment of Alzheimer’s disease and Traumatic brain injury
- Major unmet clinical need
- Valid therapeutic target with proof-of-concept
- Highly attractive lead compounds identified
Updated: October 2012
For more information, download the printable flyer.
Catalyst Therapeutics: Exploiting small molecule drug opportunities
- Investment and project management company
- Focused on early stage discovery projects involving small molecules
- Accessed via collaboration with the Walter and Eliza Hall Institute
Updated: October 2012
For more information, download the printable flyer.
Back to top
Navigation
Sponsors
